Domestic launch time of Aducanumab

The original drug Aducanumab (Aducanumab) has not been launched in China, and the specific launch time is still unclear. While the approval of aducanumab represents the first drug treatment for Alzheimer's disease, the approval is contingent on further results. The development of aducanumab was halted in March 2019 when two Phase 3 clinical trials failed to pass futility analyses. However, aducanumab received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2021. Continued approval will depend on further trials to confirm its clinical efficacy is superior to currently available treatments.